ATI-1777, a Topical Jak1/3 Inhibitor, May Benefit Atopic Dermatitis without Systemic Drug Exposure: Results from Preclinical Development and Phase 2a Randomized Control Study ATI-1777-AD-201.

Autor: Changelian P; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Xu C; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Mnich S; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Hope H; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Kostecki K; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA.; Department of Human Oncology, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin, USA., Hirsch J; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Loh CY; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA.; Miguel Hernández University of Elche, Alicante, Spain., Anderson D; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Blinn J; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Hockerman S; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Dick E; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA.; Research and Development, Context Therapeutics, Philadelphia, Pennsylvania, USA., Smith W; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Monahan J; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Raoof T; Raoof MD Dermatology, Encino, California, USA., Forman S; CenExel FCR, Tampa, Florida, USA., Burt D; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Barnes B; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Gordon D; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA.; Clinical Development, Immunology, Johnson & Johnson, West Chester, Pennsylvania, USA., Walker N; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Sudzina J; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Tucker S; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA., Jacobsen J; Aclaris Therapeutics, Chesterbrook, Pennsylvania, USA.

Publikováno v: JID innovations : skin science from molecules to population health [JID Innov] 2023 Nov 28; Vol. 4 (2), pp. 100251. Date of Electronic Publication: 2023 Nov 28 (Print Publication: 2024).

Antigenicity and Immunogenicity of Transmitted/Founder, Consensus, and Chronic Envelope Glycoproteins of Human Immunodeficiency Virus Type 1

Autor: Chen, H., Montefiori, D. C., Alam, S. M., Scearce, R. M., Haynes, B. F., Swanstrom, R., Foulger, A., Xia, S.-M., Lu, X., Blinn, J. H., Shaw, G. M., Gao, F., Liao, H.-X., Korber, B., Lapedes, A., Sutherland, L. L., Ma, B.-J., Muldoon, M., Bowman, C., Hahn, B. H., Watson, S., Vandergrift, N., Parks, R., Tsao, C.-Y.

Human immunodeficiency virus type 1 (HIV-1) vaccine development requires selection of appropriate envelope (Env) immunogens. Twenty HIV-1 Env glycoproteins were examined for their ability to bind human anti-HIV-1 monoclonal antibodies (MAbs) and then

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1534d509c4035c77e5e0a7b9ebbfdb9e

Self-Intersections of Cubic Bézier Curves Revisited.

Autor: Sánchez-Reyes, Javier¹ (AUTHOR) javier.sanchezreyes@uclm.es

Publikováno v: Mathematics (2227-7390). Aug2024, Vol. 12 Issue 16, p2463. 7p.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design.

Autor: Kwon YD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Georgiev IS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Ofek G; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Zhang B; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Asokan M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Bailer RT; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Bao A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Caruso W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Chen X; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Choe M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Druz A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Ko SY; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Louder MK; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., McKee K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., O'Dell S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Pegu A; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Rudicell RS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Shi W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Wang K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Yang Y; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Alger M; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Bender MF; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Carlton K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Cooper JW; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Blinn J; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Eudailey J; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Lloyd K; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Parks R; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Alam SM; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Haynes BF; Duke Human Vaccine Institute, Departments of Medicine, Surgery, Pediatrics and Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Center for HIV/AIDS Vaccine Immunology-Immunogen Discovery, Duke University, Durham, North Carolina, USA., Padte NN; The Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, USA., Yu J; The Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, USA., Ho DD; The Aaron Diamond AIDS Research Center, Rockefeller University, New York, New York, USA., Huang J; HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Connors M; HIV-Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Schwartz RM; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Mascola JR; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jmascola@mail.nih.gov pdkwong@nih.gov., Kwong PD; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA jmascola@mail.nih.gov pdkwong@nih.gov.

Publikováno v: Journal of virology [J Virol] 2016 Jun 10; Vol. 90 (13), pp. 5899-5914. Date of Electronic Publication: 2016 Jun 10 (Print Publication: 2016).